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Abstract
Staphylococcus aureus (S. aureus) is a human pathogen associated with skin and soft tissue infections (SSTI) and life
threatening sepsis and pneumonia. Efforts to develop effective vaccines against S. aureus have been largely unsuccessful, in
part due to the variety of virulence factors produced by this organism. S. aureus alpha-hemolysin (Hla) is a pore-forming
toxin expressed by most S. aureus strains and reported to play a key role in the pathogenesis of SSTI and pneumonia. Here
we report a novel recombinant subunit vaccine candidate for Hla, rationally designed based on the heptameric crystal
structure. This vaccine candidate, denoted AT-62aa, was tested in pneumonia and bacteremia infection models using S.
aureus strain Newman and the pandemic strain USA300 (LAC). Significant protection from lethal bacteremia/sepsis and
pneumonia was observed upon vaccination with AT-62aa along with a Glucopyranosyl Lipid Adjuvant-Stable Emulsion
(GLA-SE) that is currently in clinical trials. Passive transfer of rabbit immunoglobulin against AT-62aa (AT62-IgG) protected
mice against intraperitoneal and intranasal challenge with USA300 and produced significant reduction in bacterial burden in
blood, spleen, kidney, and lungs. Our Hla-based vaccine is the first to be reported to reduce bacterial dissemination and to
provide protection in a sepsis model of S. aureus infection. AT62-IgG and sera from vaccinated mice effectively neutralized
the toxin in vitro and AT62-IgG inhibited the formation of Hla heptamers, suggesting antibody-mediated neutralization as
the primary mechanism of action. This remarkable efficacy makes this Hla-based vaccine a prime candidate for inclusion in
future multivalent S. aureus vaccine. Furthermore, identification of protective epitopes within AT-62aa could lead to novel
immunotherapy for S. aureus infection.
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Introduction
Staphylococcus aureus (S. aureus) is a ubiquitous, formidable Gram-
positive pathogen associated with skin and soft tissue infections
(SSTI), as well as life threatening sepsis and pneumonia [1]. Since
its first emergence in the 1960s methicillin-resistant S. aureus
(MRSA) has become endemic in hospitals and healthcare settings
worldwide [2]. Since the 1990s, several community associated
MRSA strains (CA-MRSA) have emerged and are spreading
worldwide, posing a major global challenge [3,4,5]. There are
currently no vaccines available for the prevention of S. aureus
infections. The pathogenicity of S. aureus is dependent on
numerous virulence factors, including cell surface proteins,
polysaccharides, and secreted toxins. The latter cause tissue
damage, promote bacterial dissemination and metastatic growth in
distant organs, and allow the pathogen to evade the host innate
immune response [6,7]. The pore-forming a-hemolysin (Hla), also
known as a-toxin (AT), is produced by nearly all virulent strains
and is implicated in several S. aureus diseases including SSTI [8]
and pneumonia [9].
Several lines of evidence validate Hla as an important vaccine
target for prevention of S. aureus infection or complications of
disease: i) hla is encoded by a chromosomal determinant [10], and
its production has been detected in most S. aureus isolates
[11,12,13,14]; ii) a partially attenuated Hla mutant (H35L) or
a truncated Hla protect mice against S. aureus pneumonia and skin
infections [8,9,15]; and iii) passive immunization with antibodies
raised against H35L protect mice from lethal toxin challenge and
partially protect against bacterial challenge in pneumonia and skin
infection models [16]. While the H35 mutation largely abrogates
the lytic activity of Hla, a single point mutation is not considered
sufficiently safe to be developed as vaccine for human use.
Importantly, Panchal et al reported that several reverting point
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H35 mutants [17]. Furthermore, removal of 30 or 99 amino acids
at the C terminus of the H35A mutant of Hla reactivated its
hemolytic activity [18]. Therefore, there is a need to identify
subdomain mutants of Hla with an increased safety profile capable
of inducing protective immune responses.
In this study, using a rational, structure-based approach, we
designed several truncation mutants of Hla as vaccine candidates
and examined their efficacy in two models of S. aureus infection.
Importantly, this study demonstrates, for the first time, efficacy of
a Hla based vaccine candidate against S. aureus bacteremia and
distant organ bacterial seeding.
Materials and Methods
Bacteria
S. aureus strain USA300 (Los Angeles County clone, LAC) was
obtained from the NARSA repository and S. aureus strain Newman
was kindly provided by Dr. Tim Foster (Trinity College Dublin,
Ireland).
Preparation of inoculation seeds for pneumonia model
Newman or USA300 strains were grown overnight (ON) in
a volume of 20 ml in brain heart infusion (BHI) medium at 37uC,
shaking at 230 rpm using a 50 ml culture tube. Multiples of 20 ml
cultures were prepared. ON cultures were centrifuged at
3000 rpm and washed twice in PBS using the original volume
(20 ml) before pellet was re-suspended in 1 ml phosphate buffered
saline (PBS). Multiples of re-suspended pellets were combined and
mixed thoroughly on a vortex and further re-suspended with a 28
Gauge needle to keep chain formation of bacterial cells to
a minimum. Subsequently 1ml aliquots of seed culture were
prepared and stored at 280uC. Three aliquots were streaked out
at different dilutions and different time points (to test stability of
the seed) to enumerate CFU.
Preparation of inoculation culture for bacteremia model
For bacterial challenges, CA-MRSA USA300 and USA400
were grown for 18 to 24 hours in Tryptic soy broth (TSB, Difco
Laboratories, Detroit, Mich.). 10 ml of TSB in 25 ml flask was
inoculated with a single bead of S. aureus from 280uC stored bead
stock and culture grown ON at 37uC, with shaking at 230 rpm.
The culture was centrifuged at 3000 rpm at RT, washed once with
PBS and the bacterial pellet re-suspended in 1ml sterile PBS and
used for challenges as described below.
Animals
Female BALB/c mice- 6–8 weeks of age for active immunoge-
nicity studies and 10–12 weeks for passive vaccination studies-
were purchased from Charles River laboratories.
Mice were maintained under pathogen-free conditions and fed
laboratory chow and water ad libitum. All mouse work was
conducted in accordance with protocols approved by institutional
animal care and use committees (IACUC) of Nobel Life Sciences
(Gaithersburg, MD), where animal studies were conducted.
Vaccinations
For active immunogenicity studies, mice were immunized
intramuscularly (IM) three times at two weeks interval with the
antigens formulated in adjuvant. The doses of vaccine and
adjuvant are specified for each experiment in the results section.
For immunization with Al(OH)3 or AlPO4 the antigen was pre-
absorbed to adjuvant for 1 hour at a ratio of 1:7 (antigen/
adjuvant) in 50 mM Tris, pH 7.5. GLA-SE was mixed with the
antigen in PBS before injection. For passive vaccination studies,
mice were treated with 4 mg of AT62-IgG in 500 ml volume of
PBS via intraperitoneal (IP) administration 24 hours prior to
bacterial challenge.
Mouse pneumonia model
Mice were anesthetized with isoflurane and inoculated in-
tranasally (IN) with a lethal dose of S. aureus Newman or USA300
in 50 ml DPBS and were placed into the cages in a prone position
until recovery. Animals were monitored for morbidity (weight,
hunched posture, labored breathing, ruffled fur, impaired mobil-
ity) and mortality 4 times a day within the first 48 hours and then
once a day until termination of study.
Mouse bacteremia model
Female BALB/c mice were challenged via intra-peritoneal (IP)
injection with CA-MRSA USA300 in 3% mucin-PBS solution as
previously described [19]. Briefly, lypholized hog mucin type III
(Sigma Aldrich, St. Louis, Mo) was solublized to 6% (w/v) in PBS,
sterilized by autoclaving for 10 minutes and rapidly cooled on ice
for 10 – 15 minutes. For bacterial challenges, PBS washed
overnight grown USA300 bacterial cells were suspended in PBS
to an optical density of 0.15 at 600 nm, corresponding to 7610
7
CFU/ml, and then adjusted to 2610
5 CFU/ml with PBS. At the
time of challenge, bacteria and mucin solution were mixed at
equal volumes and mice injected IP with 0.5 ml corresponding to
5610
4 CFU in 3% mucin-PBS. Mice were monitored for
morbidity and mortality twice a day up for 7 days post challenge.
Determination of bacterial load during infection
In some experiments, groups of mice were euthanized at 12 h
after challenge and blood and organs (liver, combined kidneys,
lungs and spleen) were aseptically removed to determine bacterial
load. Organs were homogenized with 3.2 mm stainless steel beads
using a Bullet Blender from Next Advance Inc. (Averill Park, NY)
and were taken up in a total volume of 500 ml PBS. Blood samples
and organ homogenates were streaked out in different dilutions on
BHI agar plates and CFU were enumerated after ON incubation
at 37uC.
Plasmids, protein expression and purification
Plasmids pET24a (+):35929 (AT79aa-His), pET24a (+):64356
(AT79aa-5G-His), pET24a (+):35930 (AT-62aa-His) and pET24a
were synthesized by DNA2.0 (Menlo Park, CA). AT-50aa-His was
constructed by cloning the PCR product with NdeI and XhoI
restriction sites into pET24a(+). Forward primer: ttCATATGaaaa-
cacgtatagtcagc and reverse primer: ttCTCGAGatcacctgtttttactg-
tag were used to amplify nucleotide sequences corresponding to
the first 50aa of mature alpha toxin protein by using S. aureus
USA300 DNA template (NARSA, Chantilly, VA). These plasmids
were designed to encode the fusion proteins AT79aa with three
glycine linker, AT79aa with 5 glycine linker, AT62aa and
AT50aa, all possessing a C-terminal 6X Histidine tag. All the
alpha toxin constructs were expressed in Escherichia coli strain BL21
DE3. For the expression of the protein, bacteria were grown at
37uC and induced with 0.3 mM isopropyl-b-D thiogalactopyrano-
side (IPTG) when OD600 absorption reached 0.5. The tempera-
ture was then reduced to 25uC and the induction was continued
for another 16 hours. Cells were harvested by centrifugation at
5000 rpm for 20 minutes. The pellet was resuspended in low salt
buffer (10 mM Tris-HCl and 20 mM NaCl, pH 7.4) and treated
with 0.2 mg/mL Lysozyme. After incubation on ice for 30 min-
utes, the cells were sonicated in the presence of EDTA free
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9000 rpm for 30 minutes, the clarified cell lysate was further
treated with 1M NaCl, 2 mM Imidazole and 0.25 % CHAPS and
used for protein purification.
The proteins were bound to 5 ml Ni-NTA column (GE
Healthcare) on an AKTApurifierH (GE Healthcare) in PBS and
washed extensively in the same buffer supplemented with 1 M
NaCl and 5 mM imidazole. Elution was performed in 20 column
volumes of 0–70% of 1 M imidazole. For AT-79aa, eluted
fractions were dialyzed out of imidazole and re-purified one more
time on Ni-NTA. AT-50aa and AT-62aa eluted fractions were
concentrated with Amicon Ultra 3K filters (Millipore) and purified
further by Size Exclusion Chromatography using Superdex 75 10/
300 GL (GE Healthcare) column equilibrated in PBS with 0.5 M
NaCl and 0.25% CHAPS. The purity and identity of all the eluted
alpha toxin variants were confirmed by SDS-PAGE and Western
blot using anti-alpha toxin mAb (6C12) generated against AT-
79aa construct as the primary antibody and goat anti-mouse as the
secondary antibody. The pure proteins were dialyzed in PBS with
10% Glycerol as the storage buffer. The concentrations were
determined by bicinchoninic acid (BCA) assay and the endotoxin
levels were determined by Limulus Amoebocyte Lysate (LAL)
chromogenic endotoxin assay. The proteins were stored at 280uC
until further use.
Molecular modeling
Model building and computer calculations were performed
using the Accelrys, Inc software Discovery Studio 2.5 running on
a Dell Precision 690 running Red Hat Enterprise Linux 4.
Simulations were in vacuo and employed a CHARMM force field
with a CFF partial charge, a distance-dependent electric constant
of 1, and a temperature of 300K. Energy minimization involved
1000 steps of conjugate gradient. The crystal structure of
heptameric AT (PDB code 7AHL) [20] was selected for this
study. Peptide segments consisting of residues 1–62 and 223–236
were extracted from subunit A of the crystal structure and used as
the template for modeling candidate constructs. The peptide
segment 1–62 was energy minimized and its molecular energy was
calculated as described in Discovery Studio 2.5. Furthermore, the
1–62 peptide segment was used to generate shorter peptide
segment, such as 1–50, which were also minimized and used in
comparative analysis with one another as candidate constructs
based on calculated molecular energies. To generate the 4-strand
protein model, the 1–62 and 223–236 segments were bridged with
varying number of glycine amino acids between residues 62 and
223, and the resulting structures were subjected to energy
minimization and energy calculations. The optimal bridging
segment consisting of three glycine amino acids were found to
be minimal for forming a stable fold.
Alpha hemolysin ELISA
Blood samples were centrifuged in serum separator tubes and
serum samples were stored at 280uC until further use in ELISA.
Briefly, 96-well plates were coated with 100 ng/well of full length
alpha toxin (List Biological Laboratories, Campbell, CA) overnight
at 4uC. Plates were blocked with Starting Block buffer (Thermo
Scientific) for one hour at room temperature (RT). Serum samples
were prepared in semi-log dilutions starting from 1:100 to
1:10,000.000 in a 96-well plate using starting block buffer as
diluent. Plates were washed three times and sample dilutions were
applied in 100 ml volume/well. Plates were incubated for one hour
at RT and washed three times before applying the conjugate, goat
anti-mouse IgG (H&L)-HRP (Horse Radish Peroxidase) in starting
block buffer. Plates were incubated for one hour at RT, washed as
described above and incubated with TMB (3,39,5,59-tetramethyl-
benzidine) to detect HRP for 30 min. Optical density at 650 nm
was measured using a Versamax
TM plate reader (Molecular
Devices CA). Data analysis for full dilution curves was performed
using Softmax program.
Alpha hemolysin oligomerization inhibition assay
500 ml of 10% rabbit red blood cells (RBC) (Colorado Serum
Company, CO) with 15 mg of purified alpha toxin was incubated
on ice for 15 min. Following incubation, samples were centrifuged
at 14,000 rpm for 5 min in pre-chilled centrifuge. Supernatants
were discarded and pellet was washed with cold PBS and then re-
suspended in 100 ml of tris-buffered saline (TBS). The samples
were incubated at 37uC for 45 min for complete lysis of
erythrocytes. Negative (without toxin) and positive (with 1%
Triton X-100) controls for hemolysis were run in parallel. The
samples were then centrifuged for 10 min at 14,000 rpm and re-
suspended in 120 mlo f1 6 Laemmli buffer, divided into two
separate aliquots, one aliquot incubated at 100uC for 10 minutes
(negative oligomerization control) and others were kept on ice.
15 ml of each sample was loaded on 7–20% sodium dodecyl sulfate
(SDS)-polyacrylamide gels for electrophoresis. For Western blot,
rabbit anti-AT-62aa polyclonal antibody (IBT Bioservices
Cat#04-0010) was used in a 1:1000 dilution to detect the
monomeric and heptameric bands. For oligomerization inhibition
assay, decreasing concentrations of antibody (400–6.25 mg/ml in
two-fold dilutions) were incubated with RBC and alpha toxin at
RT prior to incubation on ice for 15 min.
Alpha hemolysin neutralization assay
Alpha hemolysin neutralization titers of mouse sera and rabbit
AT-62aa polyclonal antibodies were determined based on
neutralization of hemolysis of 2% RBC when pre-incubated with
alpha toxin (100 ng) at RT for 10 minutes before adding RBC
followed by 30 min incubation at 37uC. After incubation, cells
were centrifuged and the absorbance in the supernatant was
determined in Versamax
TM plate reader (Molecular Devices CA)
at 416 nm. Neutralization titer 50 (NT50, defined as the dilution of
the serum which neutralizes the toxicity of alpha toxin by 50%)
was determined by plotting the OD416nm in diluted serum samples
using a four parameter logistic (4-PL) curve fit. Standard serum
samples with high, medium and low NT50 were run to the assay
during each assay run.
Results
Design of recombinant a-hemolysin vaccine candidates
The functional, and cytolytic form of Hla is a pore-forming
heptamer that binds to cell surface receptor ADAM10 [21].
Crystallographic studies show that each N-terminus of Hla is
located on the top surface of the heptameric pore where it both
latches onto a neighboring subunit in an arm-in-arm manner and
lines the cis (extracellular) entrance to the channel [20]. The N-
terminal domain of Hla consists of four anti-parallel b-strands with
three of the strands within the linear sequence of 1–62 (residues
K21-D29, M34-I43, and K50-A62) and the fourth strand being
contributed by the distal amino acids F228-M234 (Figure 1A&B).
Given the positioning of the N-terminal domain and previous
reports indicating vaccine potential of a truncated N-terminal
domain (residues 1–50) [15], we hypothesized that proteins based
on stable N-terminal domain structures would produce superior
vaccine candidates. Molecular modeling was used to identify
optimal fusion proteins based on this four-strand sheet structure.
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of residues 1–62 to 228–236 (Figure 1B) were examined.
The 1–50, 1–62, and 223–236 segments were extracted from
a subunit of the AT crystal structure. The relative stabilities of the
1–50 and 1–62 segments were calculated (Table 1), suggesting that
the novel 1–62 construct may be more stable than the reported 1–
50 construct [15]. To investigate the potential of the full four-
strand sheet structure, molecular modeling was used to evaluate
different linker units that could be used to bridge Ala62 in the
third strand with Phe228 in the fourth strand, in combination with
the loop segment Gly223-Asp227. Because of their small side
chain and conformational flexibility, glycine residues were used as
the building blocks for the linkers that join Ala62 with Gly223
(Figure 1B). Six different protein models of the 4-stranded sheet
structure with varying glycine counts in their linker units were
generated and evaluated in silico. A three-glycine linker unit had
a lower calculated molecular energy than both the 1–50 and 1–62
segments (Table 1). Linkers composed of more than three glycine
amino acids are calculated to be less stable than the three-glycine
linker construct, but their folding into stable tertiary structure may
remain feasible due to the greater conformational flexibility of the
larger linkers. The results of this modeling study suggested that
a construct consisting of residues 1–62 (denoted hereafter AT-
62aa), a construct of residues 1-62-(GGG)-223-236 (denoted
hereafter AT-79aa) and constructs containing three or more
glycine amino acids would fold into functional domains.
Based on these predictions, we generated constructs for AT-
50aa, AT-62aa, and AT-79aa with a C-terminal 6xHistidine tag.
Proteins were expressed in E. coli and purified over a Ni column.
Based on the molecular modeling study, we prepared constructs
consisting of variable number of glycine amino acids, and
determined that extension of the linker to five glycines resulted
in the best protein expression, yield and purity for in vivo studies.
Therefore, a five-glycine linker AT-79aa was used in the studies
described here. Proteins were analyzed by SDS-PAGE and
Western Blot (Figure 2) and tested for endotoxin content as
described in the Materials and Methods section.
Immunogenicity of a-hemolysin vaccine candidates
The immunogenicity of the three purified proteins was
examined in BALB/c mice in combination with Alhydrogel
(Al(OH)3), aluminum phosphate (AlPO4), or Glucopyranosyl Lipid
Adjuvant-Stable Emulsion (GLA-SE) (ImmuneDesign Corp.,
Seattle, WA). Groups of five mice were immunized three times
at 2 weeks interval with 5 mg of the antigen along with different
doses of each adjuvant (Table 2). Mouse sera were tested for total
and neutralizing antibodies to wild type Hla on day 35. To
evaluate the relationship between immunogenicity and protection
from lethal challenge, mice were challenged IP on day 52 with
5610
4 CFU of S. aureus strain USA300 along with 3% Hog Mucin
and monitored for morbidity and mortality over 7 days. Total
Figure 1. Structural analysis of Hla. (A) The relative topology of 1–
62 and 1–62(GGG)–(223–236) AT constructs on the protein surface of
a subunit from the 7AHL heptameric hemolysin crystal structure. The
protein surface for the 1–62 segment is colored green, the 223–236
sequence colored dark green, and the remaining structure colored
purple. (B) Topology of the secondary structural elements in a-
hemolysin for peptide segments examined in this study.
doi:10.1371/journal.pone.0038567.g001
Table 1. Calculated Molecular energies for Hla N-terminal
constructs.
Construct (residues) Energy (kcal/mol)
1–50 22989
1–62 23660
1–62-(GGG)-223–236 23953
doi:10.1371/journal.pone.0038567.t001
Figure 2. SDS-PAGE and Western blot analysis of purified Hla
constructs. (A) SDS-PAGE. Lane 1: Biorad pre-stained protein standard;
Lane 2: AT-50aa; Lane 3: AT-62aa; Lane 4: AT-79aa. All proteins were
loaded at 1 mg/ lane and stained with Coomassie blue. (B) Western Blot.
Lane 1: Biorad pre-stained protein standard; Lane 2: AT-50aa; Lane 3:
AT-62aa; Lane 4: AT-79aa; Lane 5: Full length alpha toxin. All proteins
were detected by anti-alpha toxin mAb (6C12) generated against AT-
79aa construct.
doi:10.1371/journal.pone.0038567.g002
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purified Hla as coating antigen and seven semi-log dilutions of
sera. The ELISA titer (EC50) was defined as the dilution of the
serum resulting in 50% maximum OD (inflection point of the 4-PL
curve). Similarly, the neutralizing titer (NT50) was defined as the
dilution of the antibody resulting in 50% inhibition of the lysis of
rabbit RBCs induced by 100 ng of purified Hla.
As shown in Table 2, all mice in the no-adjuvant and control
groups consistently succumbed within 20 h of USA300 challenge,
providing a reliable measure of lethality. Very low ELISA and
undetectable NT50 titers were observed in mice vaccinated with
AT-62aa without adjuvant. Mice vaccinated with a control
vaccine (recombinant Staphylococcal enterotoxin B vaccine; STEB-
Vax) [22] along with Al(OH)3 showed no titer to Hla. In contrast,
mice survival was improved by absorption of AT-62aa to Al(OH)3.
As quantified, Al(OH)3 induced low ELISA titers with a geometric
mean of 189 and neutralizing titers below the limit of detection.
Consistent with the low antibody titers, 3 out of 5 mice in this
group succumbed within 20 h of challenge; however, two mice
survived and remained active.
Mice survival was markedly improved by using AlPO4 or GLA-
SE as adjuvants. Mice receiving the vaccine with AlPO4 showed
slightly higher antibody titers with a geometric mean of 300 and 3
out of 5 mice showed detectable neutralizing titers. All mice in this
group survived the challenge and were comparatively less morbid,
remaining active with ruffled coat in the first two days post
challenge. All mice immunized with AT-62aa along with 20 mgo f
GLA-SE showed much higher ELISA and NT50 titers with
geometric means of 2476 and 309 respectively. Consistent with the
high titers all mice survived the challenge and remained active.
Based on these promising results, we selected GLA-SE as the
adjuvant for further comparative efficacy studies.
Comparative immunogenicity and efficacy of the vaccine
candidates
Previous reports using AT-50aa protein indicated the efficacy of
this vaccine candidate against pneumonia by the S. aureus Newman
strain [15], when used with Freund’s adjuvant. Since Freund’s
adjuvant cannot be used in humans, we sought to perform
a comparative efficacy study with the three vaccine candidates
using GLA-SE, an adjuvant currently in clinical development
[23,24]. Groups of 20 mice were vaccinated intramuscularly three
times at 2 week intervals with 5 mg of AT-50aa, AT-62aa or AT-
79aa, formulated with 5 mg of GLA-SE in PBS (in an interim study
we showed that similar titers can be achieved with 5 or 20 mgo f
GLA-SE; data not shown). On day 35, mice were bled for
determination of antibody titers. As shown in Figure 3A, mice
vaccinated with AT-62aa showed robust ELISA titers against wild
type Hla with median EC50 of 2022 (range: 510–14,900). Mice
vaccinated with AT-79aa showed much lower ELISA titer with
median of 49 (range: 0–6,050) followed by mice vaccinated with
AT-50aa with a median EC50 of 11 (range: 0–1,150). Similarly,
when neutralization titers were determined in pools of serum
samples mice vaccinated with AT-62aa showed highest NT50 of
1277 followed by AT-79aa with NT50 of 213 ( `ure 3B). Neutral-
ization was below the limit of detection of this assay in the pool of
sera from AT-50aa vaccinated mice (NT50,40). For the challenge
studies, each group was broken into two subgroups of ten mice
each and challenged as described below to determine vaccine
efficacy against S. aureus pneumonia and sepsis.
Efficacy of the vaccine candidates in S. aureus USA300
bacteremia model. Groups of ten vaccinated or five con-
trol mice were challenged on day 42 by IP administration of
5610
4 CFU of S. aureus strain USA300 along with 3% Hog Mucin.
Mice were observed for signs of mortality and morbidity for
7 days. While 100% of mice vaccinated with AT-62aa or AT-79aa
and 70% of mice vaccinated with AT-50aa survived the challenge,
only one out of five control mice survived (Figure 4A). Maximal
median weight loss of surviving mice in immunized groups was 6%
of body weight. All surviving mice re-gained weight and had
a healthy appearance (smooth fur, active) by day 7.
Efficacy of the vaccine candidates in S. aureus Newman
pneumonia. The remaining ten mice from vaccinated or
control groups were challenged on day 48 by intranasal admin-
istration of 6610
7 CFU of S. aureus strain Newman. As shown in
Figure 4B, mice vaccinated with adjuvant alone or AT-50aa died
within 24–48 h. Similarly, nine out of ten mice vaccinated with
AT-79aa succumbed to infection while one mouse survived the
challenge. In contrast, mice vaccinated with AT-62aa showed
50% protection from lethal challenge with death occurring
significantly later than in the other groups. No additional mortality
was observed in this group beyond 72 hours when the mice were
Table 2. Immunogenicity of AT-62aa tested in BALB/c mice
using different adjuvants and survival upon IP challenge with
USA300.
Adjuvant
Adjuvant
dose Mouse #
ELISA
EC50
Neut titer
NT50
Time of
death
M1 361 ,64 20h
M2 658 ,64 survived
Al(OH)3 35 mg M3 198 ,64 20h
M4 69 ,64 20h
M5 75 ,64 survived
Geo Mean 189 ,64
M1 1230 127 survived
M2 18 ,64 survived
AlPO4 35 mg M3 510 ,64 survived
M4 674 127 survived
M5 320 110 survived
Geo Mean 300
M1 1800 251 survived
M2 1630 194 survived
GLA-SE 20 mg M3 1530 159 survived
M4 2540 423 survived
M5 8170 859 survived
Geo Mean 2476.5 308.9
M1 198 ,64. 20h
M2 208 ,64. 20h
No adjuvant - M3 91.5 ,64. 20h
M4 76.7 ,64. 20h
M5 307 ,64. 20h
Geo Mean 155 ,64
M1 0 ,64. 20h
Control M2 0 120 20h
vaccine: 35 mgM 3 0 ,64. 20h
(STEBVax) M4 0 ,64. 20h
+ Al(OH)3) M5 0 ,64. 20h
doi:10.1371/journal.pone.0038567.t002
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Log-Rank (Mantel-Cox) test demonstrating high significance for
protection afforded by AT-62aa when compared to both AT-50aa
and control mice (P=0.0002) and when compared to AT-79aa
(P=0.0043) (Figure 4B).
Protection against USA 300 pneumonia. Since severe
respiratory infections have been reported to be caused by
USA300 [25], the efficacy of the vaccine candidate AT-62aa
was further explored against pneumonia induced by USA300.
Mice were vaccinated three times at two weeks interval with 10 mg
of AT-62aa along with 20 mg of GLA-SE (n=5) or GLA-SE alone
(n=10). Mice were bled on day 35 to determine serum antibody
response and challenged on day 41 with 1.5610
8 CFU of
USA300. On day 35, the vaccinated mice showed antibody titers
(EC50) with a geometric mean of 4125 with a range of 2400 to
8980. Control mice showed no detectable antibody titers. While all
control mice died within 20–48 h, four out of five vaccinated mice
survived the challenge, highlighting the efficacy of AT-62aa
against USA300 induced pneumonia (Figure 4C). Surviving mice
lost 10–25% of body weight within the first 3 days of infection but
recovered from weight loss, with 2 out of 4 mice even reaching
original weights. All surviving animals were active by day 5.
Figure 3. Comparative antibody response to vaccine candi-
dates. (A) Individual serum antibody titers towards wild-type Hla
determined after three immunizations (B) Neutralization titers of
pooled sera towards wild-type Hla after three immunizations.
doi:10.1371/journal.pone.0038567.g003
Figure 4. Comparative efficacy study of vaccine candidates in
S. aureus bacteremia and pneumonia infection models. Survival
of mice vaccinated with the three vaccine candidates and control mice
after IP challenge with 5610
4 CFU of USA300 along with Hog Mucin (A)
or IN challenge with 6610
7 CFU of S. aureus strain Newman (B). Survival
of mice vaccinated with AT-62aa and challenged IN with 1.5610
8 CFU
of S. aureus USA300 (C). Symbol key: AT-50aa (open circle), AT-62aa
(black square), AT-79aa (open triangles) and mock-immunized mice
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bacteremia
We hypothesized that the remarkable efficacy observed with
AT-62aa vaccine is mediated by a protective antibody response.
To examine this hypothesis, polyclonal antibodies were raised
against purified AT-62aa in rabbits (IBT Bioservices #04–0010)
and total IgG was purified by Protein A. Naı ¨ve rabbit IgG
(Equitech-Bio, Inc., Kerryville, TX) was used as control. Groups of
10 mice were passively immunized with 4 mg of rabbit polyclonal
anti-AT62aa antibodies (AT62-IgG) or naı ¨ve rabbit IgG by IP
injection at 24 hours before challenge with 5610
4 CFU of
USA300 or 1610
5 CFU of USA400 (MW2) in 3% Hog mucin.
As shown in Figure 5A, while nine out of ten mice immunized with
naı ¨ve IgG succumbed within 48 hours, all mice immunized with
AT62-IgG showed slightly ruffled coat, remained active, and
survived the challenge. Similarly, while 80% of control mice
challenged with MW2 died within 48 h, all mice receiving AT62-
IgG survived the lethal challenge (Figure 5B).
Antibodies to AT-62aa protect against bacterial
dissemination and organ seeding
To explore the ability of antibodies induced by the vaccine
candidate AT-62aa to inhibit bacterial dissemination and/or
growth in vivo, two studies were performed using passive immuni-
zation with AT62-IgG in pneumonia and bacteremia models.
In the first experiment, two groups of 20 mice were passively
immunized, one group with 4 mg of naı ¨ve IgG and the other
group with 4 mg of AT62-IgG. After 24 hours, mice were infected
IP with 5610
4 CFU of USA300 in 3% Hog mucin. Twelve hours
after infection mice were bled, euthanized, and various organs
were sampled and homogenized. In this experiment, two of the
control mice died before the 12 hour time point and, thus, data
could be collected only from 18 control mice. All 20 mice in the
AT62-IgG treated group were alive before euthanasia for organ
sampling. CFUs were determined in blood and organ homo-
genates. Treatment with AT62-Ig resulted in drastic reduction of
bacterial burden in blood, kidney, liver, spleen, and lung,
compared to control naı ¨ve rabbit IgG-treated mice (Figure 6).
Blood CFU counts from three of 18 samples in the control group
had to be excluded from analysis since counts were above
detection limit (.300 CFU/plate) and insufficient samples were
available for further dilutions. Statistical analysis using Mann
Whitney test showed that the differences between control and
treated groups were highly significant with P value ,0.0001 in all
cases (Figure 6). These results strongly suggest that antibodies
induced by the AT-62aa antigen can be protective against
dissemination of bacteria in vivo.
In the second experiment, two groups of 10 mice were passively
immunized, one group with naı ¨ve IgG and the other group with
AT62-IgG (both at 4 mg/mouse). After 24 hours, mice were
infected intranasally with 1.3610
8 CFU of USA300. Twelve hours
after infection, mice were euthanized and blood and various
organs were sampled and homogenized. CFUs were determined in
blood and organ homogenates. Similar to results observed in
bacteremia model, treatment with AT62-IgG resulted in reduction
of bacterial burden in blood, kidney, liver, spleen, and lung
(Figure 7). Statistical analysis using Mann Whitney test showed
that the differences were significant for kidneys, liver, and lung. A
trend was also observed in blood and spleen. While nine of ten
control mice had infected spleens, five out of 10 mice treated with
AT-62-IgG showed no bacterial seeding in spleen. In sum,
antibodies induced by AT-62aa antigen can be protective against
dissemination of bacteria in vivo.
Mechanism of action studies
To delineate the mechanism of protection by AT-62aa vaccine,
we tested the effect of AT62-IgG on neutralization and oligomer-
ization of Hla. Toxin neutralization activity of the purified
polyclonal antibody was tested using rabbit red blood cells. AT62-
IgG effectively inhibited RBC lysis induced by 100 ng of purified
Hla (Toxin tech, FL) with an EC50 of 14 mg/ml (Figure 8).
Formation of Hla heptamers upon binding to cell surface
receptor is a key event in pore formation and subsequent lysis of
target cells [26]. Given the role of the N-terminal domain, we
hypothesized that antibodies to AT-62aa interfere with the
formation of Hla heptamers and consequently inhibit target cell
lysis. To examine this hypothesis, we tested the effect of AT62-IgG
on heptameric Hla (Hla7) formation in a Western blot assay. Hla
was incubated with or without increasing concentrations of the
pAbs before incubating the mixture with RBCs. The cells were
pelleted, washed, lysed, and subjected to Western blotting without
prior boiling. AT62-IgG effectively prevented the formation of the
heptameric Hla structure in a dose dependent manner (Figure 9).
Taken together, these data suggest that antibodies to AT-62aa
neutralize the activity of Hla by binding to the N-terminal domain
by preventing oligomerization and the subsequent pore formation.
(grey diamond). Statistical analysis was performed using Log-Rank
(Mantel-Cox) test.
doi:10.1371/journal.pone.0038567.g004
Figure 5. Passive protection with rabbit polyclonal AT-62aa
(AT62-IgG) in bacteremia model. Protection from lethal challenge
with S. aureus USA300 (A) or USA400 (B) after passive immunization
with polyclonal rabbit antibodies AT62-IgG (black square) compared to
mock-treated mice (grey diamond). Statistical analysis was performed
using Log-Rank (Mantel-Cox) test, P,0.0001.
doi:10.1371/journal.pone.0038567.g005
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S. aureus is a leading cause of community and hospital acquired
infections worldwide. S. aureus expresses numerous virulence
factors including a variety of toxins and other exoproteins that
are aimed at weakening the innate immune system by direct lysis
of phagocytes or inactivation of key innate response molecules,
cause tissue destruction and enable bacterial dissemination leading
to metastatic growth in distant organs, and provide the bacteria
with much needed iron by lysis of red blood cells. Given that alpha
hemolysin (Hla) plays a key role in the pathogenesis of S. aureus
infections [8,9,27], this toxin represents a prime candidate for
vaccine development or as a component of a multivalent S. aureus
vaccine. However, at present, such a crucial vaccine is not
available in the clinic. A great body of literature describes studies
performed with an experimental Hla vaccine with a single point
mutation at histidine 35. While these studies have clearly validated
Hla as a prime vaccine candidate, a toxin with a single point
mutation is not a viable candidate for human clinical development
due to safety concerns. In this study, we used a rational, structure-
based approach to design safe and effective vaccine candidates for
Hla and identified a candidate with remarkable efficacy profile
against S. aureus pneumonia and bacteremia in mouse models.
Our lead Hla vaccine candidate AT-62aa exhibits strong
immunogenicity in mice when used with two clinically tested
adjuvants (AlPO4 and GLA-SE) with significant protection shown
Figure 6. Passive protection against bacterial dissemination in bacteremia model. Bacterial burden in organs and blood was determined
after passive immunization with polyclonal AT62-IgG or naı ¨ve IgG followed by IP infection with S. aureus USA300 in 3% Hog mucin. Statistical analysis
was performed with Mann-Whitney Test with two-tailed P value (P,0.0001 for all tested CFU).
doi:10.1371/journal.pone.0038567.g006
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Newman as well as USA300 (LAC), a highly virulent CA-MRSA
strain that is currently epidemic in the US. Using a mouse
bacteremia model, we demonstrated the key role of Hla in the
infection induced lethality, and concomitantly, showed the full
protection conferred by both AT-62aa and AT-79aa against IP
challenge with USA300. While an absolute cut off for protection
was not established in this study, protected mice generally showed
higher ELISA and neutralizing antibody titers. This finding was
consistent with the ability of antibodies to AT-62aa to effectively
neutralize Hla via inhibition of Hla oligomerization and suggests
that toxin neutralization may be the primary mechanism of
protection. This notion was supported by the ability of anti AT-
62aa antibodies, passively transferred to mice before challenge, to
protect against lethality and to dramatically reduce bacterial
burden in different organs up to 4 logs. Hla is best known for its
hemolytic activity [26] but it is also reported to induce injury to
alveolar epithelial cells [28], induce the release of nitric oxide and
other inflammatory mediators [29], and cause cell death in
monocytes presumably through excessive IL-1b release [30].
Given this broad profile of activities of alpha toxin, AT-62aa
induced neutralizing antibodies may contribute to tissue pro-
tection, contain excessive inflammatory response, protect key
innate immune cells from cell death, and reduce the availability of
iron for bacterial growth.
Ragle and Bubeck-Wardenburg [15] showed that monoclonal
antibodies to the N-terminal domain of alpha toxin protect mice
against pneumonia induced by S. aureus strain Newman. A purified
Figure 7. Passive protection against bacterial dissemination in pneumonia model. Bacterial burden in organs and blood was determined
after passive immunization with polyclonal AT62-IgG or naı ¨ve IgG followed by IN infection with S. aureus USA300. Mann-Whitney Test with two-tailed
P value (P values as indicated in figures).
doi:10.1371/journal.pone.0038567.g007
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protected mice against S. aureus pneumonia, when used for
immunization with Freund’s adjuvant [15]. In contrast, when we
vaccinated mice with the purified protein representing this portion
of Hla (AT-50aa) along with GLA-SE (Figure 3) or Alhydrogel
(data not shown), very low ELISA titers were detected, neutral-
izing antibody titers were below 1:40, and all AT-50aa vaccinated
mice succumbed to lethal pneumonia (Figure 4B). The discrep-
ancy with the previously reported results [15] most likely reflects
the use of Freund’s adjuvant by Ragle and Bubeck-Wardenburg,
which is known to be an extremely potent inducer of antibody
response. However, Freund’s adjuvant cannot be used in humans
due to severe toxicity. When tested in bacteremia model, AT-50aa
provided partial protection against lethal challenge (Figure 4A),
suggesting that some level of protective response can be achieved
with AT-50aa consistent with the reported results in pneumonia
[15]. It must be noted that while Ragle and Bubeck-Wardenburg
used a GST fusion of AT-50aa, the protein used in the current
study contained only a short 6xHis tag. It is possible that the GST
tag may have additional conformational impact on the protein
further contributing to the observed efficacy.
The analysis of Hla crystal structure shows that the N-terminal
50 amino acids represent an incomplete domain consisting of two
beta strands. Our preliminary biophysical studies using circular
dichroism showed that the AT-50aa protein largely consists of
alpha helices and unstructured regions with no indication of beta
sheets (data not shown). The fusion construct AT-79aa showed
evidence of a mixture of beta sheets and alpha helices. These
structural deviations from the beta sheet structure correlate with
the reduced ability of these two proteins to induce a robust
protective immune response. We believe that the misfolding of
AT-79aa relates to the linker region connecting the third beta
sheet of the N-terminal domain to the distal F228-M234 sheet.
Our initial studies suggested that increasing the length of the linker
from 3 to 5 glycines improved the folding of the protein. We are
currently working on further testing a variety of linkers to evaluate
if a complete four beta sheet structure can be achieved and to
compare its immunogenicity to AT-62aa.
A large number of pathogens exploit the tendency of the
immune system to induce overwhelming antibody response to
immunodominant epitopes as an immune evasion strategy [31].
This tendency, coined as ‘‘deceptive imprinting’’, is hard wired in
the immune system and poses a major challenge in vaccine
development [32]. Previous reports and our unpublished data
indicate that most people have antibody titers against Hla. In
a recent study, we examined the antibody response to multiple
staphylococcal toxins in 100 patients with S. aureus bacteremia.
While all patients showed ELISA antibody titers to alpha toxin
(EC50 range: 130–89,000) only 52% had NT50 titers above 40
(Range: 1–1500, Manuscript in press; Adhikari et al, Journal of
Infectious Diseases). Importantly, in this study, an inverse
correlation between neutralizing antibodies to Hla and the
likelihood of sepsis could be established. It is a well established
strategy in the field of vaccine design to mask the dominant
epitopes and redirect the immune response towards protective
subdominant epitopes [33]. The majority of antibody response to
native Hla may be directed to non-neutralizing dominant epitopes.
Representing a key domain in Hla olgomerization, AT-62aa may
be refocusing the antibody response toward subdominant pro-
tective epitopes resulting in strong protective efficacy, a notion
consistent with previous reports of protective epitopes in the N-
terminal domain of alpha toxin [15]. We have generated a panel
of monoclonal antibodies to AT-62aa and 30% of the clones were
found to be neutralizing, suggesting a concentration of neutralizing
epitopes in this domain (unpublished data). Current efforts are
focused on identifying the protective epitope(s) that could be used
to refine our antigen design as well as potential immunotherapy
strategies for S. aureus infections.
Taken together, the results presented in this report demonstrate
that a rationally designed subunit vaccine can yield efficacy in
animal models against two major complications of S. aureus
infections. This remarkable efficacy may relate to refocusing of the
immune response to a limited number of highly protective
epitopes. Together with previous reports of Hla vaccine efficacy
in SSTI infection models [8], our attenuated and highly effective
alpha toxin antigen must be considered as an essential component
of future S. aureus vaccine.
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